VC Sofinnova ropes in €650M for biotech, medtech despite 'volatile' environment
Friday, March 27, 2026 · first reported by Fierce Biotech
Sofinnova, a prominent VC firm, has raised €650M (approximately $715M) for its biotech and medtech fund despite volatile market conditions. The fund will focus on early-stage and growth investments in the life sciences sector.
- Firm
- Sofinnova
- Asset class
- Venture
- Geography
- Europe
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
See an error?
More in Venture capital
From the same dayGot news? Send it to us →